小剂量IL-2和IFNα与TNFα联合治疗恶性肿瘤的免疫学与临床研究

Immunity studied on the patients with malignant tumor treated with low dose of IFN plus IL - 2 and TNF

目的:研究小剂量细胞因子在恶性肿瘤免疫治疗中的意义。方法:全身应用小剂量重组干扰素(ＩＦＮα２ｂ)、白细胞介素－２(ＩＬ－２)和肿瘤坏死因子(α－ＴＮＦ)联合治疗多种恶性肿瘤６０例。应用ＡＰＡＡＰ法和免疫单向扩散法(ＲＩＤ)分析了治疗前后患者外周血中Ｔ、Ｂ淋巳细胞、ＮＫ细胞、免疫球蛋白(Ｉｇ)和补体Ｃ３活性。结果:治疗１个疗程后外周血中ＣＤ４＋的Ｔ淋巴细胞和ＣＤ２３＋的Ｂ淋巴细胞显著的高于治疗前水平(Ｐ＜０．０５);ＣＤ４＋/ＣＤ８＋比值也明显增高(Ｐ＜０．０１)。免疫球蛋白(ＩｇＭ)活性亦显著的高于治疗前水平(Ｐ＜０．０５)。ＫＰＳ积分较治疗前明显增高(Ｐ＜０．００１)。治疗后细胞因子加化疗组的ＫＰＳ积分平均增高２８．５分(Ｐ＜０．００１);ＣＲ ２６例(６５．０%);ＰＲ １１例(２７．５%),总有效率８２．５%。单纯细胞因子治疗组的ＫＰＳ积分平均增高２３分(Ｐ＜０．００１);ＰＲ １３例(６５．０%),总有效率６５．０%。结论:本方案可以显著的提高多种恶性肿瘤患者的细胞免疫和体液免疫。有可能提高肿瘤的化疗效果和患者的生存质量,延长生存期。

ve:To study Clinical significance of the immuni - therapy on the patients with malignant tumor by the low dose recombinant α - IFN、IL- 2 and α- TNF. Methods:60 paitents with malignant tumor were treated by the minimal dose α IFN、 IL - 2 and α TNF;and to analyse the activity of T, B lymphocyte、NK cells and Ig、C3 in bloods of the patients with malignant tumor were easured by APAAP and RID. Results: The number of CD4± T- lymphocytes and CD23 ± Blymphocytes in bloods of the patients in back treatment was higher than the front treatment (P<0.05) ;the ratio of CD4 ± /CD8 ± T - limphocytes in back treatment also was significantly higher than the front treatment (P< 0.001) ;The activity of IgM also was significantly increased (P<0.05). The Karmorfaky integral in back treatment (mean 58.67± 14.43)was significantly higher than the front treatment (31.33± 11.99)(P <0.001). The middle and steady respones of the patients by cytoskine plus chemotherapy group was separate 65.0% and 27.5% . Conclusion: It was significant increased of cellular and humoral immunity function of an anti - carcinoma, the curative effected of chemotherapy and the quality of subsisted that of the patients of malignant tumor.